Feb 9 |
et al., NCT05780541 | PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| 22% higher mortality (p=0.77) and 44% higher hospital discharge (p=0.11). RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024. | ||
Jul 10 2023 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad355 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19 |
| Phase 1 safety and pharmacokinetic study of lufotrelvir in 25 hospitalized COVID-19 patients. No adverse events or serious adverse events were considered related to lufotrelvir. Concentrations of lufotrelvir and its active moiety increase.. | ||
Nov 11 2022 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.1035969 | Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection |
| Review of preclinical data for lufotrelvir and active metabolites for SARS-CoV-2. Lufotrelvir (PF-07304814) is a phosphate ester prodrug that is rapidly metabolized by alkaline phosphatase into the active compound PF-0835231, which suppre.. | ||
Oct 26 2022 |
et al., Clinical Pharmacology in Drug Development, doi:10.1002/cpdd.1174 | Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants |
| Phase 1 randomized, double-blind, placebo-controlled study of 15 healthy participants showing safety and tolerability of single ascending 24-hour IV infusions of lufotrelvir (PF-07304814), a phosphate prodrug protease inhibitor targeting .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.